Combination treatment with immune checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) demonstrated overall survival benefit for patients with melanoma that has spread to the brain, according to phase II study results published in The Lancet Oncology by researchers at MD Anderson Cancer Center.
Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.
